Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed?

Marty FM, Boeckh M.

Curr Opin Virol. 2011 Dec;1(6):555-62. doi: 10.1016/j.coviro.2011.10.011. Epub 2011 Nov 4. Review.

PMID:
22440913
2.

Maribavir: 1263W94, Benzimidavir, GW 1263, GW 1263W94, VP41263.

[No authors listed]

Drugs R D. 2007;8(3):188-92. Review.

PMID:
17472414
3.

Maribavir (ViroPharma).

Lu H, Thomas S.

Curr Opin Investig Drugs. 2004 Aug;5(8):898-906. Review.

PMID:
15600248
4.

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.

Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, Young JA, Rodriguez T, Maertens J, Schmitt M, Einsele H, Ferrant A, Lipton JH, Villano SA, Chen H, Boeckh M; Maribavir 1263-300 Clinical Study Group.

Lancet Infect Dis. 2011 Apr;11(4):284-92. doi: 10.1016/S1473-3099(11)70024-X. Epub 2011 Mar 21. Erratum in: Lancet Infect Dis. 2011 May;11(5):343.

PMID:
21414843
5.

Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo.

Chou S, Hakki M, Villano S.

Antiviral Res. 2012 Aug;95(2):88-92. doi: 10.1016/j.antiviral.2012.05.013. Epub 2012 Jun 1.

6.

Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.

Avery RK, Marty FM, Strasfeld L, Lee I, Arrieta A, Chou S, Tatarowicz W, Villano S.

Transpl Infect Dis. 2010 Dec;12(6):489-96. doi: 10.1111/j.1399-3062.2010.00550.x.

PMID:
20682012
7.

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study.

Winston DJ, Young JA, Pullarkat V, Papanicolaou GA, Vij R, Vance E, Alangaden GJ, Chemaly RF, Petersen F, Chao N, Klein J, Sprague K, Villano SA, Boeckh M.

Blood. 2008 Jun 1;111(11):5403-10. doi: 10.1182/blood-2007-11-121558. Epub 2008 Feb 19.

8.

Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient.

Schubert A, Ehlert K, Schuler-Luettmann S, Gentner E, Mertens T, Michel D.

BMC Infect Dis. 2013 Jul 19;13:330. doi: 10.1186/1471-2334-13-330.

9.

Maribavir: a novel antiviral agent with activity against cytomegalovirus.

Trofe J, Pote L, Wade E, Blumberg E, Bloom RD.

Ann Pharmacother. 2008 Oct;42(10):1447-57. doi: 10.1345/aph.1L065. Epub 2008 Aug 12. Review.

PMID:
18698013
10.

Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus.

Chou S, Marousek GI.

Antimicrob Agents Chemother. 2006 Oct;50(10):3470-2.

11.

Why did maribavir fail in stem-cell transplants?

Snydman DR.

Lancet Infect Dis. 2011 Apr;11(4):255-7. doi: 10.1016/S1473-3099(11)70033-0. Epub 2011 Mar 15. No abstract available.

PMID:
21414844
12.

Interim analyses in clinical trials: why do we plan them?

Fossâ SD, Skovlund E.

J Clin Oncol. 2000 Dec 15;18(24):4007-8. No abstract available.

PMID:
11118460
13.

Maribavir use in practice for cytomegalovirus infection in French transplantation centers.

Alain S, Revest M, Veyer D, Essig M, Rerolles JP, Rawlinson W, Mengelle C, Huynh A, Kamar N, Garrigue I, Kaminski H, Segard C, Presne C, Mazeron MC, Avettant-Fenoël V, Lecuit M, Lortholary O, Coaquette A, Hantz S, Leruez-Ville M, Ploy MC.

Transplant Proc. 2013 May;45(4):1603-7. doi: 10.1016/j.transproceed.2013.01.082.

PMID:
23726629
14.

Antiviral prophylaxis in haematological patients: systematic review and meta-analysis.

Yahav D, Gafter-Gvili A, Muchtar E, Skalsky K, Kariv G, Yeshurun M, Leibovici L, Paul M.

Eur J Cancer. 2009 Dec;45(18):3131-48. doi: 10.1016/j.ejca.2009.08.010. Epub 2009 Sep 30. Review.

PMID:
19796930
15.
16.

Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir.

Boutolleau D, Burrel S, Agut H.

Antiviral Res. 2011 Jul;91(1):32-5. doi: 10.1016/j.antiviral.2011.04.015. Epub 2011 May 4.

PMID:
21570426
17.

Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir.

Chou S, Marousek GI, Senters AE, Davis MG, Biron KK.

J Virol. 2004 Jul;78(13):7124-30.

18.

Cytomegalovirus UL97 kinase mutations that confer maribavir resistance.

Chou S, Wechel LC, Marousek GI.

J Infect Dis. 2007 Jul 1;196(1):91-4. Epub 2007 May 17.

PMID:
17538888
19.

Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.

Chou S.

Rev Med Virol. 2008 Jul-Aug;18(4):233-46. doi: 10.1002/rmv.574. Review.

PMID:
18383425
20.

Effect of cell culture conditions on the anticytomegalovirus activity of maribavir.

Chou S, Van Wechel LC, Marousek GI.

Antimicrob Agents Chemother. 2006 Jul;50(7):2557-9.

Supplemental Content

Support Center